摘要Objective: To systematically evaluate the effectiveness and safety of traditional Chinese medicine (TCM) in the treatment of posttransarterial chemoembolization (TACE) syndrome of primary liver cancer. Methods: CNKI, VIP database, Wanfang database, CBM, PubMed, MEDLINE, and Cochrane library were retrieved, and the RCTs of Chinese medicine in the treatment of primary liver cancer TACE postoperative syndrome were included from the establishment of the database to March 2022. The Cochrane bias risk tool was used to evaluate the quality of included articles. RevMan 5.4 software was used for metaanalysis of outcome indicators and GRADEprofiler 3.6 software was used to evaluate the quality of evidence. Results: A total of 3992 patients were included in 44 studies. Metaanalysis results showed that compared with conventional western medicine treatment, combined Chinese medicine treatment could reduce the incidence of fever [RR=1.45, 95％CI(1.09, 1.92)], nausea and vomiting [RR=1.47, 95％CI(1.10, 1.95)], liver pain [RR=1.21, 95％CI(1.02, 1.43)]; shorten the duration of fever [SMD=2.11. 95％CI(1.43, 2.79)], nausea and vomiting [SMD=1.67, 95％CI(1.22, 2.11)], hepatic pain [SMD=1.90, 95％CI(1.30, 2.51)], abdominal distension and pain [SMD=1.27, 95％CI(0.75, 1.79)], loose stool [SMD=2.30, 95％CI(1.24, 3.36)], constipation [SMD=2.18, 95％CI(1.52, 2.84)] after TACE,also it can improve patient quality of life [RR=0.73, 95％CI(0.65, 0.82)], clinical TCM syndrome [RR=0.73, 95％CI(0.65, 0.82)], shortterm efficacy [RR=0.75, 95％CI(0.66, 0.85)], oneyear survival rate [RR=0.87, 95％CI(0.78, 0.96)] and liver function and immune function. There was no significant difference in the incidence of abdominal distension and abdominal pain. Conclusion: Compared with only symptomatic western medicine after surgery, the combination of Chinese medicine has a significant effect and good safety in the treatment of postTACE syndrome.